MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
MiMedx Group, Inc. (Nasdaq: MDXG) will release its second-quarter financial results for the period ended June 30, 2022, after market close on August 2, 2022. A webcast and conference call will be hosted by senior management on August 3, 2022, at 8:30 a.m. Eastern Time to discuss these results. MiMedx specializes in placental biologics and has provided over two million allografts, focusing on treating acute and chronic non-healing wounds as well as degenerative musculoskeletal conditions.
- Scheduled financial results release may indicate strong operational activity.
- Historical provision of over two million allografts demonstrates product acceptance and demand.
- No current financial metrics provided may lead to uncertainty among investors.
MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on Wednesday, August 3, 2022, beginning at 8:30 a.m. Eastern Time.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13730760
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com
Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com
FAQ
When will MiMedx Group report its second-quarter financial results for 2022?
What time is the MiMedx Group conference call for Q2 results?
How can investors access the MiMedx Group Q2 results webcast?
What is the focus of MiMedx Group's business operations?
